EFFORT Extension Study (EFFORT-Ex)
A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial
Sponsor: Major Science and Technology Special Project of China Eleventh Five-year
Listed as NCT01529255, this PHASE4 trial focuses on Hepatitis B, Chronic and remains ongoing. Sponsored by Major Science and Technology Special Project of China Eleventh Five-year, it has been updated 6 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jan 2021 — Jul 2023 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Major Science and Technology Special Project of China Eleventh Five-year
- Nanfang Hospital, Southern Medical University
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Jinan, China , Nanjing, China , Shanghai, China and 3 more locations